{"version":"1.0","provider_name":"\u6d77\u83f2\u5c14\u5fb7\u751f\u7269\u5236\u836f","provider_url":"https:\/\/highfieldbio.com\/zh","author_name":"HighField Bio","author_url":"https:\/\/highfieldbio.com\/zh\/author\/highfield-bio\/","title":"HighField Biopharmaceuticals Files INDs for Two ADCplex\u2122 Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs - HighField Biopharmaceuticals","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"omRtLJbGMk\"><a href=\"https:\/\/highfieldbio.com\/zh\/2025\/04\/21\/highfield-files-inds-for-two-adcplex-immunoliposomes\/\">HighField Biopharmaceuticals \u63d0\u4ea4\u4e24\u79cd\u5177\u6709\u4e0d\u540c\u6297\u764c\u6d3b\u6027\u7684 ADCplex\u2122 \u514d\u75ab\u8102\u8d28\u4f53 IND \u7533\u8bf7\uff0c\u4ee5\u514b\u670d\u5f53\u524d ADC \u7684\u5c40\u9650\u6027<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/highfieldbio.com\/zh\/2025\/04\/21\/highfield-files-inds-for-two-adcplex-immunoliposomes\/embed\/#?secret=omRtLJbGMk\" width=\"600\" height=\"338\" title=\"\u300aHighField Biopharmaceuticals \u63d0\u4ea4\u4e24\u6b3e\u5177\u6709\u4e0d\u540c\u6297\u764c\u6d3b\u6027\u7684 ADCplex\u2122 \u514d\u75ab\u8102\u8d28\u4f53 IND \u7533\u8bf7\uff0c\u4ee5\u514b\u670d\u73b0\u6709 ADC \u7684\u5c40\u9650\u6027\u300b\u2014HighField Biopharmaceuticals\" data-secret=\"omRtLJbGMk\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/highfieldbio.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/highfieldbio.com\/wp-content\/uploads\/2025\/04\/HIGHIELD_LinkedIn_INDfiles.jpg","thumbnail_width":1200,"thumbnail_height":800,"description":"HighField Biopharmaceuticals Files INDs for Two ADCplex\u2122 Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs The new technology behind HighField\u2019s immunoliposomes may offer greater safety and efficacy than existing antibody drug conjugates (ADCs) HANGZHOU, China &#8211; April 21, 2025 &#8211;HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer [&hellip;]"}